"This final sentence carries a lot of information. It does put a lid on the scale of the placement - my guess is around $100m which should limit the dilution pain. More importantly, it rules out any chance of FDA approval of any product in the near future. I would not put much weight on Novartis coming to the rescue either."
FFS, have you never heard of accelerated approval with phase 4 confirmatory trials?
Ann: Half Year Report and Accounts (including Appendix 4D), page-88
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |